Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market

Description

List of Tables

The global Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 9,954,720.47 thousand by 2030, from USD 4,577,440.16 thousand in 2022, growing at the CAGR of 10.6% in the forecast period of 2023 to 2030.

Market Segmentation

Global Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina, Peru, Rest of South America - Industry Trends and Forecast to 2030.

Overview of Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics

Driver
Increasing prevalence and incidence of acute lung injury in the market
Restraint
High cost of device and treatment
Opportunity
Strategic initiatives joined with new product launches by market players

Market Players

Some of the major market players operating in the global Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below:

Gilead Sciences, Inc.
Terumo Medical Corporation
Getinge
LivaNova PLC
Medtronic
ResMed
Fisher & Paykel Healthcare Limited.
Dragerwerk AG & Co. KGaA
NIPRO
Fresenius SE & Co. KGaA
Hamilton Medical
Pfizer Inc.
WEINMANN Emergency Medical Technology GmbH + Co. KG
EUROSETS
Armstrong Medical
nice Neotech Medical Systems Pvt. Ltd.
Besmed Health Business Corp.

1 INTRODUCTION 41

1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43

2 MARKET SEGMENTATION 45

2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 MULTIVARIATE MODELLING 51
2.7 TYPE LIFELINE CURVE 51
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.9 DBMR MARKET POSITION GRID 53
2.10 MARKET END USER COVERAGE GRID 54
2.11 VENDOR SHARE ANALYSIS 55
2.12 SECONDARY SOURCES 56
2.13 ASSUMPTIONS 56

3 EXECUTIVE SUMMARY 57

4 PREMIUM INSIGHTS 60

4.1 PESTEL ANALYSIS 61
4.2 PORTER'S FIVE FORCES 62
4.3 INSURANCE REIMBURSEMENT 63
- 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 63
- 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 63
- 4.3.3 ABBOTT CODING GUIDE FOR ECMO 64
- 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 64
- 4.3.5 CERN HEALTH INSURANCE SCHEME 65
- 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 65
- 4.3.7 AMERICAN HOSPITAL ASSOCIATION 66
4.4 PIPELINE ANALYSIS 67
4.5 PRICING ANALYSIS 69

5 MARKET OVERVIEW 70

5.1 DRIVERS 72
- 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 72
- 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 72
- 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 73
- 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 73
5.2 RESTRAINTS 74
- 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 74
- 5.2.2 HIGH COST OF DEVICES AND TREATMENT 74
5.3 OPPORTUNITIES 75
- 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 75
- 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 75
- 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 76
5.4 CHALLENGES 77
- 5.4.1 STRINGENT RULES & REGULATIONS 77
- 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 78

6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 79

6.1 OVERVIEW 80
6.2 MECHANICAL VENTILATION 83
- 6.2.1 HIGH-FLOW NASAL O2 84
- 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 84
- 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 84
- 6.2.4 PRONE POSITION VENTILATION 84
- 6.2.5 OTHERS 85
6.3 CORTICOSTEROIDS 85
- 6.3.1 METHYLPREDNISOLONE 86
- 6.3.2 DEXAMETHASONE 86
- 6.3.3 OTHERS 86
6.4 ANTIVIRAL MEDICATION 87
- 6.4.1 RIBAVIRIN 88
- 6.4.2 OSELTAMIVIR 88
- 6.4.3 OTHERS 88
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 88
6.6 TOCILIZUMAB 89
6.7 OTHERS 89

7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 90

7.1 OVERVIEW 91
7.2 SEPSIS 94
7.3 INHALATION OF HARMFUL SUBSTANCES 94
7.4 SEVERE PNEUMONIA 95
7.5 OTHERS 95

8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 96

8.1 OVERVIEW 97
8.2 PARENTERAL 100
- 8.2.1 INTRAVENOUS 100
- 8.2.2 INTRAMUSCULAR 100
8.3 ORAL 101
8.4 OTHERS 101

9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 102

9.1 OVERVIEW 103
9.2 HOSPITALS 106
9.3 SPECIALTY CLINICS 106
9.4 HOME HEALTHCARE 107
9.5 OTHERS 107

10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 108

10.1 OVERVIEW 109
10.2 DIRECT TENDER 112
10.3 HOSPITAL PHARMACY 112
10.4 RETAIL PHARMACY 113
10.5 ONLINE PHARMACY 113

11 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 114

11.1 OVERVIEW 115
11.2 NORTH AMERICA 118
- 11.2.1 U.S. 123
- 11.2.2 CANADA 128
- 11.2.3 MEXICO 133
11.3 EUROPE 138
- 11.3.1 GERMANY 143
- 11.3.2 FRANCE 148
- 11.3.3 U.K. 153
- 11.3.4 ITALY 158
- 11.3.5 SPAIN 163
- 11.3.6 TURKEY 168
- 11.3.7 NETHERLANDS 173
- 11.3.8 SWITZERLAND 178
- 11.3.9 BELGIUM 183
- 11.3.10 RUSSIA 188
- 11.3.11 REST OF EUROPE 193
11.4 ASIA-PACIFIC 194
- 11.4.1 JAPAN 200
- 11.4.2 CHINA 205
- 11.4.3 INDIA 210
- 11.4.4 SOUTH KOREA 215
- 11.4.5 AUSTRALIA 220
- 11.4.6 SINGAPORE 225
- 11.4.7 THAILAND 230
- 11.4.8 MALAYSIA 235
- 11.4.9 INDONESIA 240
- 11.4.10 PHILIPPINES 245
- 11.4.11 REST OF ASIA-PACIFIC 250
11.5 SOUTH AMERICA 251
- 11.5.1 BRAZIL 256
- 11.5.2 ARGENTINA 261
- 11.5.3 REST OF SOUTH AMERICA 266
11.6 MIDDLE EAST AND AFRICA 267
- 11.6.1 SOUTH AFRICA 272
- 11.6.2 SAUDI ARABIA 277
- 11.6.3 U.A.E 282
- 11.6.4 ISRAEL 287
- 11.6.5 EGYPT 292
- 11.6.6 KUWAIT 297
- 11.6.7 REST OF MIDDLE EAST AND AFRICA 302

12 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 303

12.1 COMPANY SHARE ANALYSIS: GLOBAL 303
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304
12.3 COMPANY SHARE ANALYSIS: EUROPE 305
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306

13 SWOT ANALYSIS 307

14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 308

14.1 GILEAD SCIENCES INC. 308
- 14.1.1 COMPANY SNAPSHOT 308
- 14.1.2 REVENUE ANALYSIS 309
- 14.1.3 COMPANY SHARE ANALYSIS 309
- 14.1.4 PRODUCT PORTFOLIO 310
- 14.1.5 RECENT DEVELOPMENT 310
14.2 TERUMO CORPORATION 311
- 14.2.1 COMPANY SNAPSHOT 311
- 14.2.2 REVENUE ANALYSIS 311
- 14.2.3 COMPANY SHARE ANALYSIS 312
- 14.2.4 PRODUCT PORTFOLIO 312
- 14.2.5 RECENT DEVELOPMENT 312
14.3 GETINGE 313
- 14.3.1 COMPANY SNAPSHOT 313
- 14.3.2 REVENUE ANALYSIS 313
- 14.3.3 COMPANY SHARE ANALYSIS 314
- 14.3.4 PRODUCT PORTFOLIO 314
- 14.3.5 RECENT DEVELOPMENT 314
14.4 LIVANOVA PLC 315
- 14.4.1 COMPANY SNAPSHOT 315
- 14.4.2 REVENUE ANALYSIS 315
- 14.4.3 COMPANY SHARE ANALYSIS 316
- 14.4.4 PRODUCT PORTFOLIO 316
- 14.4.5 RECENT DEVELOPMENTS 316
14.5 MEDTRONIC 317
- 14.5.1 COMPANY SNAPSHOT 317
- 14.5.2 REVENUE ANALYSIS 317
- 14.5.3 COMPANY SHARE ANALYSIS 318
- 14.5.4 PRODUCT PORTFOLIO 318
- 14.5.5 RECENT DEVELOPMENTS 318
14.6 ARMSTRONG MEDICAL 319
- 14.6.1 COMPANY SNAPSHOT 319
- 14.6.2 PRODUCT PORTFOLIO 319
- 14.6.3 RECENT DEVELOPMENT 319
14.7 BESMED HEALTH BUSINESS CORP. 320
- 14.7.1 COMPANY SNAPSHOT 320
- 14.7.2 PRODUCT PORTFOLIO 320
- 14.7.3 RECENT DEVELOPMENTS 321
14.8 DRAGERWERK AG & CO. KGAA 322
- 14.8.1 COMPANY SNAPSHOT 322
- 14.8.2 REVENUE ANALYSIS 322
- 14.8.3 PRODUCT PORTFOLIO 323
- 14.8.4 RECENT DEVELOPMENTS 323
14.9 EUROSETS 324
- 14.9.1 COMPANY SNAPSHOT 324
- 14.9.2 PRODUCT PORTFOLIO 324
- 14.9.3 RECENT DEVELOPMENT 324
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 325
- 14.10.1 COMPANY SNAPSHOT 325
- 14.10.2 REVENUE ANALYSIS 325
- 14.10.3 PRODUCT PORTFOLIO 326
- 14.10.4 RECENT DEVELOPMENTS 326
14.11 FRESENIUS SE & CO. KGAA. 327
- 14.11.1 COMPANY SNAPSHOT 327
- 14.11.2 REVENUE ANALYSIS 327
- 14.11.3 PRODUCT PORTFOLIO 328
- 14.11.4 RECENT DEVELOPMENT 328
14.12 HAMILTON MEDICAL 329
- 14.12.1 COMPANY SNAPSHOT 329
- 14.12.2 PRODUCT PORTFOLIO 329
- 14.12.3 RECENT DEVELOPMENT 329
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 330
- 14.13.1 COMPANY SNAPSHOT 330
- 14.13.2 PRODUCT PORTFOLIO 330
- 14.13.3 RECENT DEVELOPMENT 330
14.14 NIPRO 331
- 14.14.1 COMPANY SNAPSHOT 331
- 14.14.2 REVENUE ANALYSIS 331
- 14.14.3 PRODUCT PORTFOLIO 332
- 14.14.4 RECENT DEVELOPMENT 332
14.15 PFIZER INC. 333
- 14.15.1 COMPANY SNAPSHOT 333
- 14.15.2 REVENUE ANALYSIS 333
- 14.15.3 PRODUCT PORTFOLIO 334
- 14.15.4 RECENT DEVELOPMENT 334
14.16 RESMED 335
- 14.16.1 COMPANY SNAPSHOT 335
- 14.16.2 REVENUE ANALYSIS 335
- 14.16.3 PRODUCT PORTFOLIO 336
- 14.16.4 RECENT DEVELOPMENT 336
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 337
- 14.17.1 COMPANY SNAPSHOT 337
- 14.17.2 PRODUCT PORTFOLIO 337
- 14.17.3 RECENT DEVELOPMENT 337

15 QUESTIONNAIRE 338

16 RELATED REPORTS 341

LIST OF TABLES

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT 69
TABLE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 82
TABLE 3 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 4 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 83
TABLE 5 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 84
TABLE 6 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 84
TABLE 7 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 8 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 85
TABLE 9 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 86
TABLE 10 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 86
TABLE 11 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 12 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 87
TABLE 13 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 87
TABLE 14 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 87
TABLE 15 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 16 GLOBAL TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 17 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 93
TABLE 19 GLOBAL SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 20 GLOBAL INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 21 GLOBAL SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 22 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 99
TABLE 24 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 25 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 100
TABLE 26 GLOBAL ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
TABLE 27 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
TABLE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 29 GLOBAL HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 30 GLOBAL SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 31 GLOBAL HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 32 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 111
TABLE 34 GLOBAL DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 35 GLOBAL HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 36 GLOBAL RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 113
TABLE 37 GLOBAL ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 113
TABLE 38 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 118
TABLE 40 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 41 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 42 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 119
TABLE 43 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 44 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 120
TABLE 45 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 46 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 120
TABLE 47 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 120
TABLE 48 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 49 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 50 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 51 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 52 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 53 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 54 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 124
TABLE 55 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 124
TABLE 56 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 57 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 125
TABLE 58 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 125
TABLE 59 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 60 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 125
TABLE 61 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 126
TABLE 62 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 126
TABLE 63 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
TABLE 64 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 65 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 66 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 68 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 69 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 129
TABLE 70 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 129
TABLE 71 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 72 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 130
TABLE 73 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 130
TABLE 74 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 75 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 130
TABLE 76 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 131
TABLE 77 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 131
TABLE 78 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
TABLE 79 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
TABLE 80 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 81 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 132
TABLE 82 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 83 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 84 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 134
TABLE 85 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 134
TABLE 86 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 87 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 134
TABLE 88 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 135
TABLE 89 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 90 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 135
TABLE 91 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 135
TABLE 92 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 136
TABLE 93 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 94 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 95 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 96 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 97 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 138
TABLE 98 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 99 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 100 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 140
TABLE 101 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 102 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 140
TABLE 103 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 104 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 141
TABLE 105 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 141
TABLE 106 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
TABLE 107 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 142
TABLE 108 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 142
TABLE 109 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 142
TABLE 110 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 111 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 112 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 144
TABLE 113 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 144
TABLE 114 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 115 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 145
TABLE 116 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 145
TABLE 117 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 118 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 145
TABLE 119 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 146
TABLE 120 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 146
TABLE 121 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
TABLE 122 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 147
TABLE 123 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
TABLE 124 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 147
TABLE 125 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 126 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 127 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 149
TABLE 128 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 149
TABLE 129 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 130 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 150
TABLE 131 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 150
TABLE 132 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 133 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 150
TABLE 134 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 151
TABLE 135 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 151
TABLE 136 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 151
TABLE 137 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
TABLE 138 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 152
TABLE 139 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 152
TABLE 140 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 141 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 142 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 154
TABLE 143 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 154
TABLE 144 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 145 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 155
TABLE 146 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 155
TABLE 147 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 148 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 155
TABLE 149 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 156
TABLE 150 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 156
TABLE 151 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
TABLE 152 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 157
TABLE 153 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 157
TABLE 154 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 155 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 156 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 157 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 159
TABLE 158 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 159
TABLE 159 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 160 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 160
TABLE 161 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 160
TABLE 162 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 163 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 160
TABLE 164 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 161
TABLE 165 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 161
TABLE 166 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 161
TABLE 167 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 162
TABLE 168 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 162
TABLE 169 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 162
TABLE 170 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 171 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 172 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 164
TABLE 173 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 164
TABLE 174 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 175 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 165
TABLE 176 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 165
TABLE 177 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 178 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 165
TABLE 179 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 166
TABLE 180 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 166
TABLE 181 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 166
TABLE 182 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 167
TABLE 183 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 167
TABLE 184 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 167
TABLE 185 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 186 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 187 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 169
TABLE 188 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 169
TABLE 189 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 190 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 170
TABLE 191 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 170
TABLE 192 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 193 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 170
TABLE 194 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 171
TABLE 195 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 171
TABLE 196 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 171
TABLE 197 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 172
TABLE 198 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 172
TABLE 199 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 172
TABLE 200 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 201 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 202 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 174
TABLE 203 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 174
TABLE 204 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 174
TABLE 205 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 175
TABLE 206 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 175
TABLE 207 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 175
TABLE 208 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 175

TABLE 209 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 176
TABLE 210 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 176
TABLE 211 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 176
TABLE 212 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 177
TABLE 213 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 177
TABLE 214 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 177
TABLE 215 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 216 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 217 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 179
TABLE 218 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 179
TABLE 219 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 179
TABLE 220 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 180
TABLE 221 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 180
TABLE 222 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 180
TABLE 223 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 180
TABLE 224 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 181
TABLE 225 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 181
TABLE 226 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 181
TABLE 227 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 182
TABLE 228 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 182
TABLE 229 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 182
TABLE 230 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 183
TABLE 231 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 183
TABLE 232 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 184
TABLE 233 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 184
TABLE 234 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 184
TABLE 235 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 185
TABLE 236 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 185
TABLE 237 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 185
TABLE 238 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 185
TABLE 239 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 186
TABLE 240 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 186
TABLE 241 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 186
TABLE 242 BELGIUM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 187
TABLE 243 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 187
TABLE 244 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
TABLE 245 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 246 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 247 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 189
TABLE 248 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 189
TABLE 249 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 189
TABLE 250 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 189
TABLE 251 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 190
TABLE 252 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 190
TABLE 253 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 190
TABLE 254 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 190
TABLE 255 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 191
TABLE 256 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 191
TABLE 257 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 191
TABLE 258 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 192
TABLE 259 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 192
TABLE 260 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 193
TABLE 261 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 194
TABLE 262 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 195
TABLE 263 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 195
TABLE 264 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 196
TABLE 265 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 196
TABLE 266 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 196
TABLE 267 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 197
TABLE 268 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 197
TABLE 269 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 197
TABLE 270 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 198
TABLE 271 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 198
TABLE 272 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 198
TABLE 273 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 199
TABLE 274 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 200
TABLE 275 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 200
TABLE 276 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 201
TABLE 277 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 201
TABLE 278 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 201
TABLE 279 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 202
TABLE 280 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 202
TABLE 281 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 202
TABLE 282 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 202
TABLE 283 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 203
TABLE 284 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 203
TABLE 285 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 203
TABLE 286 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 204
TABLE 287 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 204
TABLE 288 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 204
TABLE 289 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 205
TABLE 290 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 205
TABLE 291 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 206
TABLE 292 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 206
TABLE 293 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 206
TABLE 294 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 207
TABLE 295 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 207
TABLE 296 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 207
TABLE 297 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 207
TABLE 298 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 208
TABLE 299 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 208
TABLE 300 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 208
TABLE 301 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 209
TABLE 302 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 209
TABLE 303 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 209
TABLE 304 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 210
TABLE 305 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 210
TABLE 306 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 211
TABLE 307 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 211
TABLE 308 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 211
TABLE 309 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 212
TABLE 310 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 212
TABLE 311 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 212
TABLE 312 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 212
TABLE 313 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 213
TABLE 314 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 213
TABLE 315 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 213
TABLE 316 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 214
TABLE 317 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 214
TABLE 318 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 214
TABLE 319 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 215
TABLE 320 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 215
TABLE 321 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 216
TABLE 322 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 216
TABLE 323 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 216
TABLE 324 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 217
TABLE 325 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 217
TABLE 326 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 217
TABLE 327 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 217
TABLE 328 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 218
TABLE 329 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 218
TABLE 330 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 218
TABLE 331 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 219
TABLE 332 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 219
TABLE 333 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 219
TABLE 334 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 220
TABLE 335 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 220
TABLE 336 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 221
TABLE 337 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 221
TABLE 338 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 221
TABLE 339 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 222
TABLE 340 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 222
TABLE 341 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 222
TABLE 342 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 222
TABLE 343 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 223
TABLE 344 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 223
TABLE 345 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 223
TABLE 346 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 224
TABLE 347 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 224
TABLE 348 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 224
TABLE 349 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 225
TABLE 350 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 225
TABLE 351 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 226
TABLE 352 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 226
TABLE 353 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 226
TABLE 354 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 227
TABLE 355 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 227
TABLE 356 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 227
TABLE 357 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 227
TABLE 358 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 228
TABLE 359 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 228
TABLE 360 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 228
TABLE 361 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 229
TABLE 362 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 229
TABLE 363 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 229
TABLE 364 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 230
TABLE 365 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 230
TABLE 366 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 231
TABLE 367 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 231
TABLE 368 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 231
TABLE 369 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 232
TABLE 370 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 232
TABLE 371 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 232
TABLE 372 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 232
TABLE 373 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 233
TABLE 374 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 233
TABLE 375 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 233
TABLE 376 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 234
TABLE 377 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 234
TABLE 378 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 234
TABLE 379 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 235
TABLE 380 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 235
TABLE 381 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 236
TABLE 382 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 236
TABLE 383 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 236
TABLE 384 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 237
TABLE 385 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 237
TABLE 386 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 237
TABLE 387 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 237
TABLE 388 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 238
TABLE 389 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 238
TABLE 390 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 238
TABLE 391 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 239
TABLE 392 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 239
TABLE 393 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 239
TABLE 394 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 240
TABLE 395 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 240
TABLE 396 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 241
TABLE 397 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 241
TABLE 398 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 241
TABLE 399 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 242
TABLE 400 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 242
TABLE 401 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 242
TABLE 402 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 242
TABLE 403 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 243
TABLE 404 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 243
TABLE 405 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 243
TABLE 406 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 244
TABLE 407 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 244
TABLE 408 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 244
TABLE 409 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 245
TABLE 410 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 245
TABLE 411 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 246
TABLE 412 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 246
TABLE 413 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 246
TABLE 414 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 247
TABLE 415 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 247
TABLE 416 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 247
TABLE 417 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 247

LIST OF FIGURES

FIGURE 1 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 45
FIGURE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION 48
FIGURE 3 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS 49
FIGURE 4 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 50
FIGURE 5 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS 50
FIGURE 6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS 52
FIGURE 7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID 53
FIGURE 8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID 54
FIGURE 9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS 55
FIGURE 10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 59
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 60
FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030 60
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 71
FIGURE 14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022 80
FIGURE 15 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 81
FIGURE 16 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 81
FIGURE 17 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE 82
FIGURE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022 91
FIGURE 19 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND) 92
FIGURE 20 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030) 92
FIGURE 21 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE 93
FIGURE 22 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 97
FIGURE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 98
FIGURE 24 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 98
FIGURE 25 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 99
FIGURE 26 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022 103
FIGURE 27 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 104
FIGURE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030) 104
FIGURE 29 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE 105
FIGURE 30 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 109
FIGURE 31 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 110
FIGURE 32 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 110
FIGURE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 111
FIGURE 34 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022) 116
FIGURE 35 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 303
FIGURE 36 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 304
FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 305
FIGURE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 306